Dr. Addison R. Tolentino, MD - Overland ...

Dr. Addison R. Tolentino

Claim this profile

Saint Luke's Hospital of Kansas City

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
6 reported clinical trials
14 drugs studied

Area of expertise

1Lung Cancer
Addison R. Tolentino has run 5 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Addison R. Tolentino has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.
Saint Luke's Hospital Of Kansas City
Image of trial facility.
Saint Luke's South Hospital

Clinical Trials Addison R. Tolentino is currently running

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

More about Addison R. Tolentino

Clinical Trial Related11 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Addison R. Tolentino has experience with
  • Carboplatin
  • Pembrolizumab
  • Axillary Lymph Node Dissection (ALND)
  • Axillary Radiation Therapy
  • Nodal Radiation Therapy
  • Biospecimen Collection

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Addison R. Tolentino specialize in?
Is Addison R. Tolentino currently recruiting for clinical trials?
Are there any treatments that Addison R. Tolentino has studied deeply?
What is the best way to schedule an appointment with Addison R. Tolentino?
What is the office address of Addison R. Tolentino?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security